About 600 results
Open links in new tab
  1. Agios

    Since our founding, Agios has been a pioneering leader in cellular metabolism, advancing therapies for patients with unmet needs. Our mature and unique understanding of the science is foundational to …

  2. About Us - Agios

    Agios was founded in 2008 to unlock a new field of discovery in cellular metabolism. This singular focus on metabolic disease has taken us from the development of precision therapies in oncology to …

  3. Pipeline – Agios

    Agios is committed to creating value for shareholders by creating value for patients and healthcare providers. Find out how in our latest press releases and SEC filings, upcoming events and other …

  4. Leadership – Agios

    At Agios, leadership means building stronger bonds with colleagues, partners and patient communities and honoring each of their perspectives to make the process of developing life-changing treatments …

  5. Our Medicines – Agios

    Agios offers the myAgios ® patient support services program as a single point of engagement for eligible patients, including access support, prescription fulfillment, financial assistance, disease education …

  6. History – Agios

    As we create the future of Agios together, we are building on our core values and pioneering leadership in cellular metabolism to advance our work on behalf of people with rare diseases.

  7. Contact – Agios

    Agios Pharmaceuticals 88 Sidney Street Cambridge, MA 02139-4169 Phone: 617-649-8600

  8. Medical – Agios

    At Agios, we are studying how PK activation could potentially benefit people with SCD. PK activation modulates 2,3-diphosphoglycerate (2,3-DPG) levels in RBCs which reduces hemoglobin S …

  9. U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of ...

    Dec 24, 2025 · Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.

  10. News – Agios

    Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition Read More 10/30/2025 Press Release